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IL-36   
To the Editor,  
Monocyte Chemotactic Protein-1-Induced Protein 1 (MCPIP1; also 
known as Regnase-1 and encoded by the ZC3H12A gene) is a negative 
regulator of inflammatory processes [1,2]. MCPIP1 possesses a con-
served CCCH-type zinc finger domain and PilT N-terminus (PIN) do-
main with RNase properties [1,3]. It recognizes specific stem-loop 
structures in 3′ untranslated regions and mediates the destabilization of 
transcripts encoding, for example, pro-inflammatory cytokines and 
transcription factors [1–3]. Previous studies indicated that MCPIP1 is 
both transcriptionally and translationally activated in the human 
psoriatic epidermis [4,5]. It was further discovered that Mcpip1 defi-
ciency contributes to enhanced sensitivity to imiquimod (IMQ). In 
particular, heterozygous Mcpip1−/+ mice developed IMQ-induced 
psoriasiform inflammation faster than control mice [6]. This phenotype 
was not attributed to changes in the mRNA expression of interleukin-23 
(IL-23)/T-helper 17 (Th17) cytokines but rather was due to enhanced 
IL-17 receptor (IL-17r) signalling [6]. In addition, a recent study by 
Takaishi et al. showed that the loss of Mcpip1 expression in keratino-
cytes led to an exaggerated response to IMQ stimulation, similar to 
what was shown in heterozygous Mcpip1−/+ mice. The authors in-
dicated proved the involvement of IL-36r signalling in the development 
of the psoriasis-like phenotype. However, Mcpip1EKO:IL-36rKO mice 
were only partially protected against IMQ-induced skin inflammation 
[7]. Based on those reports, we hypothesized that additional factors 
drive the enhanced sensitivity of keratinocyte-specific Mcpip1-deficient 
(Mcpip1EKO) mice to IMQ-driven skin inflammation. 
To address this question, we utilized a classic model of psoriasis-like 
skin inflammation induced by IMQ [8]. We previously showed that 
upon ageing, Mcpip1EKO mice develop spontaneous skin pathology, 
most likely as a result of elevated inflammatory signalling [9]. Kerati-
nocyte-specific ablation of Mcpip1 upregulated the transcriptional ex-
pression of genes related to inflammation and keratinocyte differ-
entiation, such as Il36a, Il36g, S100a8, S1000a9, Defb3, Sprr2d and 
Sprr2h [7,9]. To induce psoriasis-like inflammation, we applied IMQ- 
containing cream to the shaved backs of control and Mcpip1EKO mice 
for four consecutive days (Fig. 1A). Topical IMQ treatment resulted in 
the accelerated development of psoriasis-like skin symptoms in Mcpi-
p1EKO mice, as indicated by an abrupt increase in the Psoriasis Area and 
Severity Index (PASI) score (Fig. 1B and Suppl. Fig. S1A). Histological 
analyses performed 96 h after IMQ application confirmed the psoriasis- 
specific pathology of the skin, which was characterized by epidermal 
skin thickening (acanthosis), hyperkeratosis, and the retention of nuclei 
within corneocytes (parakeratosis) (Fig. 1C). The major phenotypical 
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T
changes observed in psoriatic skin develop via abnormal proliferation 
and differentiation of keratinocytes. To investigate these processes in 
our model, skin sections were stained for keratin 14 (Krt14), a marker 
of basal keratinocytes, and Krt10, which is expressed in suprabasal 
differentiating epidermal cells. Immunohistochemistry showed a re-
duction in keratinocytes expressing Krt10 with the simultaneous in-
creased expression of Krt14 in suprabasal epidermal layers, indicating 
the abnormal differentiation and accelerated proliferation of Mcpip1EKO 
(caption on next page) 
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keratinocytes compared to control keratinocytes following 96 h of 
treatment with IMQ (Suppl. Fig. S1B). We also noticed a mild pro-
liferation/differentiation disturbance phenotype in mock-treated 
Mcpip1EKO mouse skin (Fig. 1C and Suppl. Fig. S1B). 
Subsequently, we examined the kinetics with which histological 
features of psoriasis develop in our system. Comparison of the histo-
logical morphology of IMQ-treated Mcpip1EKO and control mouse skin 
revealed that Mcpip1 loss led to a more dynamic increase in epidermal 
thickness upon IMQ application. Compared to the control mouse epi-
dermis, the Mcpip1EKO mouse epidermis was almost 2-fold thicker in 
response to treatment with IMQ for only 24 h and remained sig-
nificantly elevated after 48 h (Fig. 1D). Accordingly, in both groups of 
mice, increased proliferation, assessed by staining for proliferating cell 
nuclear antigen (PCNA), was observed 48 h after IMQ application; 
however, this effect was much more pronounced in Mcpip1EKO mice 
(Fig. 1E). At this time point, we also observed the increased infiltration 
of Gr1+ cells (neutrophils and monocytes) to IMQ-treated Mcpip1EKO 
skin. It was previously shown that neutrophils accumulated in the skin 
of haploinsufficient Mcpip1−/+ mice following IMQ treatment [6]. In 
this study, we report that specific ablation of keratinocyte Mcpip1 is 
sufficient to promote Gr1+ cells infiltration into the skin during the 
early stages of IMQ-induced inflammation (Fig. 1F). 
Having characterized the major histological features of skin in-
flammation induced by IMQ, we attempted to explore molecular factors 
that contribute to the accelerated development of psoriasiform in-
flammation in Mcpip1EKO mice. Several psoriasis-associated factors are 
commonly described, among which the IL-23/Th17 axis plays a crucial 
role [10]. IL-23 promotes the development of IL-17- and IL-22-produ-
cing Th17 cells. Psoriatic lesions are characterized by elevated ex-
pression of IL-23 and increased numbers of Th17 cells. Both IL-17 and 
IL-23 cytokines enhance dermal acanthosis, neutrophil recruitment and 
the infiltration of IL-22- and IL-17-producing cells into lesional skin 
[11]. In a recent study, Takaishi and colleagues did not observe sig-
nificant differences between Mcpip1EKO mice and control mice in terms 
of IMQ-induced IL-23/Th17 axis mRNA levels after 72 h of IMQ treat-
ment [7], similar to what was previously shown in heterozygous 
Mcpip1−/+ mice by Monin et al. [6]. In agreement with these ob-
servations, we did not observe significant differences in the relative 
expression levels of Il17a, Il22 and Il23a transcripts after 96 h of IMQ 
stimulation (Suppl. Fig. S2A). 
We hypothesized that the mechanisms that trigger psoriasis-like 
inflammation are very abruptly activated in Mcpip1EKO mice. In addi-
tion to measuring gene expression levels at 96 h, we performed analyses 
at earlier time points following IMQ application. To that end, samples 
for qRT-PCR analyses were collected at 12 and 24 h following initial 
IMQ application (Fig. 1A and G). We observed that the IMQ-induced 
mRNA expression of a plethora of pro-inflammatory mediators in 
Mcpip1EKO skin was already altered within the first 24 h. In particular, 
transcript levels of the major IL-23/Th17 cytokines IL-17a, IL-22 and IL- 
23 in the whole skin of Mcpip1EKO mice were significantly increased 
after 12 and 24 h following IMQ application (Fig. 1G). Consistently, 
transcriptional expression of the Il6, Il33, S100a9, Sprr2d and Cxcl2 
genes, which are related to inflammation, keratinocyte differentiation 
and antimicrobial defence and associated with the psoriatic phenotype, 
was abruptly induced in Mcpip1EKO mouse skin, with kinetics similar to 
those of the activation of genes encoding IL-23/Th17 cytokines 
(Fig. 1G). The expression patterns of selected mRNAs explain the abrupt 
development of the psoriasis-like phenotype in Mcpip1EKO mice. 
Next, we investigated the activation of Stat3 signalling, which plays 
an important role in Th17 cell biology and has been implicated in the 
pathogenesis of psoriasis and other autoimmune inflammatory diseases, 
in our model of psoriasis-like inflammation [12,13]. The transcriptional 
regulator STAT3 was identified as an acute phase response factor ac-
tivated by IL-6 [11]. STAT3 is also regulated by other factors, including 
IL-17, IL-22 and IL-23 [14,15]. Our studies indicate that the treatment 
of both control and Mcpip1EKO mouse skin with IMQ for 96 h led to the 
activation of Stat3 (Suppl. Fig. S2B). In addition, detailed analysis of the 
kinetics of Stat3 phosphorylation revealed that in Mcpip1EKO mice, 
Stat3 was activated 12 and 24 h after IMQ application with simulta-
neous transcriptional activation of pro-psoriatic cytokines (Fig. 1H and 
Suppl. Fig. S3A). 
Altogether, in this study, we showed that depletion of Mcpip1 in 
keratinocytes led to a highly aggravated skin inflammation phenotype 
upon the IMQ-mediated induction of psoriasis-like skin inflammation. 
IMQ treatment greatly accelerated the induction of pro-psoriatic gene 
expression in Mcpip1EKO mice, which was associated with the appear-
ance of histological inflammatory features and neutrophil infiltration. 
In particular, we showed that the loss of keratinocyte Mcpip1 led to 
enhanced proliferation and reduced differentiation and neutrophil ac-
cumulation in response to stimulation with IMQ. 
To the best of our knowledge, this is the first study to utilize such 
short-term application (12–24 h) of IMQ. Using this approach, we 
identified psoriasis-associated molecular factors that were rapidly ac-
tivated in the skin of Mcpip1EKO mice. In particular, we showed that IL- 
23/Th17 cytokine mRNA levels varied significantly between control 
and Mcpip1EKO mouse skin at very early time points upon stimulation 
with IMQ. In line with this, the level of IL-23 protein was elevated in 
Mcpip1EKO skin treated with IMQ for 24 h (Suppl. Fig. S3B). 
Consistently with this observation, the IL-17a blockade significantly 
weakened the IMQ-induced inflammatory phenotype of Mcpip1EKO 
mice (Fig. 1I and J) suggesting that the inflammatory phenotype must, 
at least partially, depend on IL-23/Th17 pathway. Thus, our results may 
explain why inhibiting IL-36 signalling only partially protected Mcpi-
p1EKO mice against IMQ-induced skin inflammation. Most likely, the IL- 
23/Th17, IL-33 and IL-36 axes are together involved in the rapid de-
velopment of psoriasiform dermatitis in mice with keratinocyte-specific 
ablation of Mcpip1. Our work expands current knowledge of the role of 
the Mcpip1 protein in modulating psoriasis-like inflammation. It also 
indicates that factors controlling the posttranscriptional regulation of 
inflammatory gene expression may contribute to skin diseases and act 
as potential therapeutic targets. 
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Fig. 1. Mcpip1 deficiency promotes psoriasiform dermatitis. (A) A schematic diagram of a 96-h time course of IMQ application. (B) Disease severity during IMQ 
treatment; n = 5 (3 independent experiments). Clinical scores for disease severity were calculated daily using a scoring system based on the clinical Psoriasis Area 
and Severity Index (PASI); n = 5. For statistical analysis, IMQ-treated Mcpip1EKO mice were compared to IMQ-treated control mice. (C) Microscopic analysis of H&E- 
stained dorsal skin sections at 96 h. Scale bar: 100 μm. (D) Microscopic measurement of the epidermal thickness of back skin at 24 and 48 h; n = 3. (E) 
Immunostaining for PCNA at 48 h. Scale bar: 50 μm. (F) Immunohistochemical staining of Gr1+ cells at 48 h. Scale bar: 100 μm. (G) Total RNA was isolated from 
control and Mcpip1EKO mock/IMQ-treated mouse skin. qRT-PCR analysis of Il17a, Il22, Il23a, Il6, Il33, S100a9, Sprr2d and Cxcl2 expression levels was carried out. Ef2 
was used as a reference gene; n = 4. (H) Representative Western blot among three independent experiments to detect p-Stat3 and total Stat3 from whole-skin protein 
lysates. β-Actin was used as a loading control. (I-J) Mcpip1EKO mice ears were treated with IMQ for 96 h in the presence of IL-17a or isotype control antibodies (I) Ear 
swelling; n = 5–6 (3 independent experiments). (J) Microscopic analysis of H&E-stained ear sections at 96 h and microscopic measurement of the ear epidermal 
thickness; n = 5–6. Data are shown as the mean and SEM. The dashed line indicates the basal membrane. IMQ – imiquimod; epi – epidermis; der – dermis; hf – hair 
follicle; ND – not detected by qRT-PCR (a value of zero was given for statistics). Two-way ANOVA or unpaired t-test (I and J) was used to calculate P-values. Asterisks 
indicate statistically significant differences. *P  <  0.05, **P  <  0.01, ***P  <  0.001. 
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